Inflammation modifies the platelet reactivity among thrombocytopenia patients undergoing percutaneous coronary intervention

References

• Freynhofer MK, Bruno V, Wojta J, Huber K. The role of platelets in athero-thrombotic events. Curr Pharm Des. 2012;18(33):5197–9. doi:10.2174/138161212803251899.
   PubMed Web of Science ®Google Scholar
• Berkowitz SD, Sane DC, Sigmon KN, Shavender JH, Harrington RA, Tcheng JE, Topol EJ, Califf RM. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the prevention of ischemic complications (EPIC) study group. J Am Coll Cardiol. 1998;32(2):311–9. doi:10.1016/s0735-1097(98)00252-6.
   PubMed Web of Science ®Google Scholar
• WANG TY, OU FS, ROE MT, Harrington RA, Ohman EM, Gibler WB, Peterson ED. Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. Circulation. 2009;119(18):2454–62. doi:10.1161/circulationaha.108.827162.
   PubMed Web of Science ®Google Scholar
• Ranucci M, Baryshnikova EFTS, CLinical Outcome Research Score G. The interaction between preoperative platelet count and function and its relationship with postoperative bleeding in cardiac surgery. Platelets. 2017;28(8):794–8. doi:10.1080/09537104.2017.1280148.
   PubMed Web of Science ®Google Scholar
• Ayoub K, Marji M, Ogunbayo G, Masri A, Abdel-Latif A, Ziada K, Vallurupalli S. Impact of chronic thrombocytopenia on in-hospital outcomes after percutaneous coronary intervention. JACC Cardiovasc Interv. 2018;11(18):1862–8. doi:10.1016/j.jcin.2018.05.033.
   PubMed Web of Science ®Google Scholar
• Yadav M, Genereux P, Giustino G, Madhavan MV, Brener SJ, Mintz G, Caixeta A, Xu K, Mehran R, Stone GW, et al. Effect of baseline thrombocytopenia on ischemic outcomes in patients with acute coronary syndromes who undergo percutaneous coronary intervention. Can J Cardiol. 2016;32(2):226–33. doi:10.1016/j.cjca.2015.05.020.
   PubMed Web of Science ®Google Scholar
• Overgaard CB, Ivanov J, Seidelin PH, Todorov M, Mackie K, Džavík V. Thrombocytopenia at baseline is a predictor of inhospital mortality in patients undergoing percutaneous coronary intervention. Am Heart J. 2008;156(1):120–4. doi:10.1016/j.ahj.2008.02.003.
   PubMed Web of Science ®Google Scholar
• Roh JW, Lim S, HWang Y, Lee KY, Choo EH, Choi IJ, Hwang B-H, Kim CJ, Park M-W, Kim D-B, et al. Ischemic and bleeding events associated with thrombocytopenia and thrombocytosis after percutaneous coronary intervention in patients with acute myocardial infarction. J Clin Med. 2020;9(10):3370. doi:10.3390/jcm9103370.
   PubMed Web of Science ®Google Scholar
• Wada H, Dohi T, Miyauchi K, Shitara J, Endo H, Doi S, Naito R, Konishi H, Tsuboi S, Ogita M, et al. Preprocedural high-sensitivity C-reactive protein predicts long-term outcome of percutaneous coronary intervention. Circ J. 2016;81(1):90–5. doi:10.1253/circj.CJ-16-0790.
   PubMed Web of Science ®Google Scholar
• Duewell P, KOno H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nuñez G, Schnurr M, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464(7293):1357–61. doi:10.1038/nature08938.
   PubMed Web of Science ®Google Scholar
• ANdic N, Gunduz E, AKay OM, Şahin D, Teke HÜ. Cardiac and pulmonary thrombosis during multidrug treatment in an idiopathic thrombocytopenic purpura patient. Platelets. 2014;25(1):69–70. doi:10.3109/09537104.2012.758360.
   PubMed Web of Science ®Google Scholar
• Mcfadyen JD, Stevens H, Peter K. The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications. Circ Res. 2020;127(4):571–87. doi:10.1161/circresaha.120.317447.
   PubMed Web of Science ®Google Scholar
• Stark K, Massberg S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol. 2021;18(9):666–82. doi:10.1038/s41569-021-00552-1.
   PubMed Web of Science ®Google Scholar
• Zhao X, Jiang L, Xu L, Tian J, Xu Y, Zhao Y, Feng X, Wu Y, Zhang Y, Wang D, et al. Predictive value of in-hospital white blood cell count in Chinese patients with triple-vessel coronary disease. Eur J Prev Cardiol. 2019;26(8):872–82. doi:10.1177/2047487319826398.
   PubMed Web of Science ®Google Scholar
• Li J, Yuan D, Jiang L, Tang X, Xu J, Song Y, Chen J, Qiao S, Yang Y, Gao R, et al. Similar inflammatory biomarkers reflect different platelet reactivity in percutaneous coronary intervention patients treated with clopidogrel: a large-sample study from China. Front Cardiovasc Med. 2021;8:736466. doi:10.3389/fcvm.2021.736466.
   PubMedGoogle Scholar
• Collet JP, THiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–367. doi:10.1093/eurheartj/ehaa575.
   PubMed Web of Science ®Google Scholar
• Neumann FJ, Sousa-uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet J-P, Falk V, Head SJ, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. EuroIntervention. 2019;14(14):1435–534. doi:10.4244/eijy19m01_01.
   PubMed Web of Science ®Google Scholar
• Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, et al. Guidelines on myocardial revascularization. Eur Heart J. 2010;31(20):2501–55. doi:10.1093/eurheartj/ehq277.
   PubMed Web of Science ®Google Scholar
• Levine GN, BAtes ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American college of cardiology foundation/American heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. J Am Coll Cardiol. 2011;58(24):e44–122. doi:10.1016/j.jacc.2011.08.007.
   PubMed Web of Science ®Google Scholar
• RIdker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836–43. doi:10.1056/nejm200003233421202.
   PubMed Web of Science ®Google Scholar
• Ridker PM. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J. 2016;37(22):1720–2. doi:10.1093/eurheartj/ehw024.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31. doi:10.1056/NEJMoa1707914.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. doi:10.1182/blood-2016-03-643544.
   PubMed Web of Science ®Google Scholar
• Lewis B. Thrombocytopenia and outcome in invasive cardiology. J Invasive Cardiol, 2002;14 Suppl B:38b–47b.
   PubMedGoogle Scholar
• Tantry US, Bonello L, ARadi D, Price MJ, Jeong Y-H, Angiolillo DJ, Stone GW, Curzen N, Geisler T, ten Berg J, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62(24):2261–73. doi:10.1016/j.jacc.2013.07.101.
   PubMed Web of Science ®Google Scholar
• Galimzhanov A, Sabitov Y, Tenekecioglu E, Tun HN, Alasnag M, Mamas MA. Baseline platelet count in percutaneous coronary intervention: a dose–response meta-analysis. Heart. 2022;108(22):1792–9. doi:10.1136/heartjnl-2022-320910.
   Web of Science ®Google Scholar
• Montalescot G, Rangé G, Silvain J, Bonnet J-L, Boueri Z, Barthélémy O, Cayla G, Belle L, Van Belle E, Cuisset T, et al. High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: a landmark analysis of the ARCTIC study. Circulation. 2014;129(21):2136–43. doi:10.1161/circulationaha.113.007524.
   PubMed Web of Science ®Google Scholar
• Patti G, NUsca A, Mangiacapra F, Gatto L, D’Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (antiplatelet therapy for reduction of myocardial damage during angioplasty-platelet reactivity predicts outcome) study. J Am Coll Cardiol. 2008;52(14):1128–33. doi:10.1016/j.jacc.2008.06.038.
   PubMed Web of Science ®Google Scholar
• Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation. 2009;119(2):237–42. doi:10.1161/circulationaha.108.812636.
   PubMed Web of Science ®Google Scholar
• Han X, Li C, Zhang S, Hou X, Chen Z, Zhang J, Zhang Y, Sun J, Wang Y. Why thromboembolism occurs in some patients with thrombocytopenia and treatment strategies. Thromb Res. 2020;196:500–9. doi:10.1016/j.thromres.2020.10.005.
   PubMed Web of Science ®Google Scholar
• Guan WJ, Ni ZY, Hu Y, Liang W-H, Ou C-Q, He J-X, Liu L, Shan H, Lei C-L, Hui DSC, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. doi:10.1056/NEJMoa2002032.
   PubMed Web of Science ®Google Scholar
• Mei H, Luo L, Hu Y. Thrombocytopenia and thrombosis in hospitalized patients with COVID-19. J Hematol Oncol. 2020;13(1):161. doi:10.1186/s13045-020-01003-z.
   PubMed Web of Science ®Google Scholar
• Handtke S, Thiele T. Large and small platelets-(when) do they differ? J Thromb Haemost, 2020, 18(6): 1256–67. DOI: 10.1111/jth.14788.
   PubMed Web of Science ®Google Scholar
• Boulware R, Refaai MA. Why do patients with immune thrombocytopenia (ITP) experience lower bleeding events despite thrombocytopenia? Thromb Res. 2020;187:154–8. doi:10.1016/j.thromres.2020.01.020.
   PubMed Web of Science ®Google Scholar
• Davizon-castillo P, Mcmahon B, Aguila S, Bark D, Ashworth K, Allawzi A, Campbell RA, Montenont E, Nemkov T, D’Alessandro A, et al. TNF-α–driven inflammation and mitochondrial dysfunction define the platelet hyperreactivity of aging. Blood. 2019;134(9):727–40. doi:10.1182/blood.2019000200.
   PubMed Web of Science ®Google Scholar
• Demopoulos C, Antonopoulou S, Theoharides TC. COVID-19, microthromboses, inflammation, and platelet activating factor. Biofactors. 2020;46(6):927–33. doi:10.1002/biof.1696.
   PubMed Web of Science ®Google Scholar
• Lordan R, Tsoupras A, Zabetakis I, Demopoulos CA. Forty years since the structural elucidation of platelet-activating factor (PAF): historical, Current, and future research perspectives. Molecules. 2019;24(23):4414. doi:10.3390/molecules24234414.
   PubMed Web of Science ®Google Scholar
• Semeraro F, Ammollo CT, Morrissey JH, Dale GL, Friese P, Esmon NL, Esmon CT. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood. 2011;118(7):1952–61. doi:10.1182/blood-2011-03-343061.
   PubMed Web of Science ®Google Scholar
• Biino G, Balduini CL, Casula L, Cavallo P, Vaccargiu S, Parracciani D, Serra D, Portas L, Murgia F, Pirastu M, et al. Analysis of 12,517 inhabitants of a Sardinian geographic isolate reveals that predispositions to thrombocytopenia and thrombocytosis are inherited traits. Haematologica. 2011;96(1):96–101. doi:10.3324/haematol.2010.029934.
   PubMed Web of Science ®Google Scholar
• Hakim DA, Dangas GD, Caixeta A, Nikolsky E, Lansky AJ, Moses JW, Claessen B, Sanidas E, White HD, Ohman EM, et al. Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the harmonizing outcomes with revascularization and stents in acute myocardial infarction (HORIZONS-AMI) trial. Am Heart J. 2011;161(2):391–6. doi:10.1016/j.ahj.2010.11.001.
   PubMed Web of Science ®Google Scholar
• Park S, Ahn JM, Kim TO, Park H, Cho S-C, Kang D-Y, Lee PH, Park D-W, Park S-J. Incidence and impact of thrombocytopenia in patients undergoing percutaneous coronary intervention with drug-eluting stents. Am J Cardiol. 2020;134:55–61. doi:10.1016/j.amjcard.2020.07.059.
   PubMed Web of Science ®Google Scholar
• Urban L, Ingrid Š, Žolková J, Ján S, Bolek T, Samoš M. High on-treatment platelet reactivity in patients undergoing complex percutaneous coronary interventions. Clin Appl Thromb Hemost. 2023;29:10760296231199089. doi:10.1177/10760296231199089.
   Web of Science ®Google Scholar
• Siller-matula JM, Trenk D, Schrör K, Gawaz M, Kristensen SD, Storey RF, Huber K. Response variability to P2Y12 receptor inhibitors: expectations and reality. JACC Cardiovasc Interv. 2013;6(11):1111–28. doi:10.1016/j.jcin.2013.06.011.
   PubMed Web of Science ®Google Scholar
• Siller-matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol. 2008;52(19):1557–63. doi:10.1016/j.jacc.2008.07.055.
   PubMed Web of Science ®Google Scholar